SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
SCYNEXIS, Inc. (SCYX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $42.14 per share as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $42.14.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $5.78.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.46.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.72.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $42.14 10-Q · filed 2026-08-10 |
| 2026-03-31 | $5.78 10-Q · filed 2026-05-11 |
| 2025-12-31 | $6.46 10-K · filed 2026-03-04 |
| 2025-09-30 | $6.72 10-Q · filed 2025-11-05 |
| 2025-06-30 | $7.05 10-Q · filed 2025-08-13 |
| 2025-03-31 | $8.57 10-Q · filed 2025-05-15 |
| 2024-12-31 | $10.60 10-K · filed 2025-03-12 |
| 2024-09-30 | $11.20 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.78 10-Q · filed 2024-08-08 |
| 2024-03-31 | $13.35 10-Q · filed 2024-05-08 |
| 2023-12-31 | $13.92 10-K · filed 2024-03-28 |
| 2023-09-30 | $14.18 10-Q · filed 2023-11-13 |
| 2023-06-30 | $14.48 10-Q · filed 2023-08-14 |
| 2023-03-31 | $15.70 10-Q · filed 2023-05-10 |
| 2022-12-31 | $15.85 10-K · filed 2023-03-31 |
| 2022-09-30 | $18.11 10-Q · filed 2022-11-09 |
| 2022-06-30 | $19.24 10-Q · filed 2022-08-15 |
| 2022-03-31 | $21.77 10-Q · filed 2022-05-12 |
| 2021-12-31 | $22.73 10-K · filed 2022-03-29 |
| 2021-09-30 | $24.03 10-Q · filed 2021-11-10 |
| 2021-06-30 | $26.62 10-Q · filed 2021-08-16 |
| 2021-03-31 | $29.27 10-Q · filed 2021-05-17 |
| 2020-12-31 | $31.47 10-K · filed 2021-03-29 |
| 2020-09-30 | $33.06 10-Q · filed 2020-11-06 |
| 2020-06-30 | $35.22 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.89 10-Q · filed 2020-05-11 |
| 2019-12-31 | $4.17 10-K · filed 2020-03-11 |
| 2019-09-30 | $4.32 10-Q · filed 2019-11-12 |
| 2019-06-30 | $4.96 10-Q · filed 2019-08-07 |
| 2019-03-31 | $5.43 10-Q · filed 2019-05-08 |
| 2018-12-31 | $5.77 10-K · filed 2019-03-14 |
| 2018-09-30 | $5.99 10-Q · filed 2018-11-13 |
| 2018-06-30 | $6.27 10-Q · filed 2018-08-09 |
| 2018-03-31 | $6.73 10-Q · filed 2018-05-08 |
| 2017-12-31 | $7.19 10-K · filed 2019-03-14 |
| 2017-09-30 | $7.40 10-Q · filed 2017-11-07 |
| 2017-06-30 | $7.72 10-Q · filed 2017-08-08 |
| 2017-03-31 | $8.26 10-Q · filed 2017-05-08 |
| 2016-12-31 | $8.59 10-K · filed 2018-03-13 |
| 2015-12-31 | $9.41 10-K · filed 2017-03-13 |
| 2014-12-31 | $9.44 10-K · filed 2016-03-07 |
| 2013-12-31 | $23.26 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |